Abstract
Amyloid was for more than a century considered to be an interesting, unique, but inconsequential tissue deposit which rarely caused significant clinical problems. We now recognize that there are many forms of amyloid. Amyloid represents a uniform organization of a disease-, or pathological process-, specific protein which is combined with a set of common structural components. Furthermore, amyloid is not the rare entity it was originally thought to be. It has become implicated in the pathogenesis of diseases which affect millions of patients. These range from common disorders such as Alzheimer’s diseases, adult-onset diabetes, and consequences of prolonged dialysis, to the historically recognized rare systemic forms associated with inflammation and plasma cell disturbances. Strong evidence is emerging that even when amyloid is deposited in local organ sites significant physiologic effects may ensue. By all criteria, such as scientific curiosity, incidence, medical importance, and commercial markets, amyloid has come of age.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Axelrad, M.A., Kisilevsky, R., Willmer, J., Chen, S.J., and Skinner, M., 1982, Further characterization of amyloid enhancing factor, Lab. Invest. 47:139–146.
Baltz, M.L., Caspi, D., Evans, D.J., Rowe, I.F., Hind, C.R.K., and Pepys, M.B., 1986, Ciculating amyloid P component is the precursor of amyloid P component in tissue amyloid deposits, Clin. Exp. Immunol. 66:691–700.
Benson, M.D., and Uemichi, T., 1996, Transthyretin amyloidosis, Amyloid 3:44–56.
Bons, N., Mestre, N., and Petter, A., 1992, Senile Plaques and Neurofibrillary Changes in the Brain of an Aged Le-murian Primate, Microcebus-Murinus, Neurobiol Aging 13:99–105.
Breuer, W., Colbatzky, F., Platz, S., and Hermanns, W., 1993, Immunoglobulin-Producing Tumours in Dogs and Cats,J.Comp. Pathol. 109:203–216.
Clark, A., Dekoning, E.JP., and Morris, J.F., 1993, Formation of Islet Amyloid from Islet Amyloid Polypeptide, Biochem. Soc. Trans. 21:169–176.
Colon, W., Lai, Z.H., Mccutchen, S.L., Miroy, G.J., Strang, C., and Kelly, J.W., 1996, FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation, Ciba Foundation Symposium 199:228–242.
Cummings, B.J., Su, J.H., Cotman, C.W., White, R., and Russell, M.J., 1993, beta-Amyloid Accumulation in Aged Canine Brain-A Model of Early Plaque Formation in Alzheimer’s Disease, Neurobiol. Aging 14:547–560.
Durie, B.G.M., Persky, B., Soehnlen, B.J., Grogan, T.M., and Salmon, S.E., 1982, Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages, N. Engl. J. Med. 307:1689–1692.
Gallo, G., Wisniewski, T., Choi-Miura, N.H., Ghiso, J., and Frangione, B., 1994, Potential role of apolipoprotein-E in fibrillogenesis, Am. J. Pathol 145:526–530.
Gearing, M., Rebeck, G.W., Hyman, B.T., Tigges, J., and Mirra, S.S., 1994, Neuropathology and apolipoprotein E profile of aged chimpanzees: Implications for Alzheimer disease, Proc. Natl. Acad. Sci. USA 91:9382–9386.
Ghetti, B., Piccardo, P., Frangione, B., Bugiani, O., Giaccone, G., Young, K., Prelli, F., Farlow, M.R., Dlouhy, S.R., and Tagliavini, F., 1996, Prion protein amyloidosis, Brain Pathol. 6:127–145.
Graether, S.P., Young, I.D., and Kisilevsky, R., 1996, Early detection of inflammation-associated amyloid in murine spleen using thioflavin T fluorescence of spleen homogenates: Implications for amyloidogenesis, Amyloid 3:20–27.
Greenberg, B.D., Savage, M.J., Howland, D.S., Ali, S.M., Siedlak, S.L., Perry, G., Siman, R., and Scott, R.W., 1996, APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology, Neurobiol. Aging 17:153–171.
Hellman, U., Wernstedt, C., Westermark, P., Obrien, T.D., Rathbun, W.B., and Johnson, K.H., 1990, Amino Acid Sequence from Degu Islet Amyloid-Derived Insulin Shows Unique Sequence Characteristics, Biochem. Biophys. Res. Commun. 169:571–577.
Higuchi, K., Yonezu, T., Kogishi, K., Matsumura, A., Takeshita, S., Higuchi, Ka., Kohno, A., Matsushita, M, Hosakawa, M., and Takeda, T., 1986a, Purification and characterization of a senile amyloid related anti-genic substance (apoSASsam) from mouse serum. ApoSASsam is an apoA-II apolipoprotein of mouse high density lipoproteins, J. Biol. Chem. 261:12834–12840.
Higuchi, K., Yonezu, T., Tsunasawa, S., Sakiyama, F., and Takeda, T., 1986b, The single proline-glutamine substitution at position 5 enhances the potency of amyloid fibril formation of murine apoA-II, FEBS Lett. 207:23–27.
Higuchi, K., Naiki, H., Kitagawa, K., Hosokawa, M., and Takeda, T., 1991, Mouse Senile Amyloidosis-ASSAM Amyloidosis in Mice Presents Universally As a Systemic Age-Associated Amyloidosis, Virchows Arch. B Cell Pathol. 60:231–238.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F.S., and Cole, G., 1996, Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice, Science 274:99–102.
Husby, G., 1994. Classification of Amyloidosis. In: Clinical Rheumatology: Vol.8 No.3, Reactive Amyloidosis and the Acute Phase Response, Husby, G., Ed., Bailiiere Tindall, London, pp. 503–511.
Ikeda, S., Tokuda, T., Yanagtsawa, N., Kametani, F., Ohshima, T., and Allsop, D., 1994, Variability of beta-amyloid protein deposited lesions in Down’s syndrome brains, Tohoku J. Exp. Med. 174:189–198.
Johnson, K.H., Westermark, P., Sletten, K., and Obrien, T.D., 1996, Amyloid proteins and amyloidosis in domestic animals, Amyloid 3:270–289.
Kazatchkine, M.D., Husby, G., Araki, S., Benditt, E.P., Benson, M.D., Cohen, A.S., Frangione, B., Glenner, G.G., Natvig, J.B., and Westermark, P., 1993, Nomenclature of Amyloid and Amyloidosis-WHO-IUIS Nomenclature Sub-Committee, Bull. WHO 71:105–108.
Kisilevsky, R., 1996, Anti-amyloid drugs: Potential in the treatment of diseases associated with aging, Drug Aging 8:75–83.
Kisilevsky, R., and Boudreau, L., 1983, The kinetics of amyloid deposition: I. The effect of amyloid enhancing factor and splenectomy, Lab. Invest. 48:53–59.
Kisilevsky, R., and Young, I.D., 1994. Pathogenesis of amyloidosis. In: Clinical Rheumatology: Vol.8 No.3, Reactive Amyloidosis and the Acute Phase Response, pp. 613–626. Husby, G., Ed., Bai liiere Tindall, London.
Levy-Lahad, E., and Bird, T.D., 1996, Genetic factors in Alzheimer’s disease: A review of recent advances, Ann. Neurol. 40:829–840.
Liepnieks, J.J., DiBartola, S.P., and Benson, M.D., 1996, Systemic immunoglobulin (AL) amyloidosis in a cat: Complete primary structure of a feline lambda light chain, Amyloid 3:177–182.
Linke, R.P., Geisel, O., and Mann, K., 1991, Equine Cutaneous Amyloidosis Derived from an Immunoglobulin lambda-Light Chain-Immunohistochemical, Immunochemical and Chemical Results, Biol. Chem. Hoppe-Seyler 372:835–843.
Lorenzo, A., and Yankner, B.A., 1994, beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red, Proc. Natl. Acad. Sci. USA 91:12243–12247.
Lyon, A.W., Narindrasorasak, S., Young, I.D., Anastassiades, T., Couchman, J.R., McCarthy, K., and Kisilevsky, R., 1991, Co-deposition of basement membrane components during the induction of murine splenic AA amyloid, Lab. Invest. 64:785–790.
Martin, L.J., Sisodia, S.S., Koo, E.H., Cork, L.C., Dellovade, T.L., Weidemann, A., Beyreuther, K., Masters, C., and Price, D.L., 1991, Amyloid Precursor Protein in Aged Nonhuman Primates, Proc. Natl. Acad. Sci. USA 88:1461–1465.
McCubbin, W.D., Kay, C.M., Narindrasorasak, S., and Kisilevsky, R., 1988, Circular dichroism and fluorescence studies on two murine serum amyloid A proteins, Biochem.J. 256:775–783.
McCutchen, S.L., Colon, W., and Kelly, J.W., 1993, Transthyretin Mutation Leu-55-Pro Significantly Alters Tetra-mer Stability and Increases Amyloidogenicity, Biochemistry 32:12119–12127.
Nagata, Y, Tashiro, F., Yi, S., Murakami, T., Maeda, S., Takahashi, K., Shimada, K., Okamura, H., and Yamamura, K., 1995, A 6-kb upstream region of the human transthyretin gene can direct developmental, tissue-specific, and quantitatively normal expression in transgenic mouse, J. Biochem. Tokyo 117:169–17
Naiki, H., Higuchi, K., Yonezu, T., Hosokawa, M., and Takeda, T., 1988, Metabolism of Senile Amyloid Precursor and Amyloidogenesis: Age-related Acceleration of Apolipoprotein A-II Clearance in the Senescence Accelerated Mouse, Am. J. Pathol. 130:579–587.
Narindrasorasak, S., Altman, R.A., Gonzalez-DeWhitt, P., Greenberg, B.D., and Kisilevsky, R., 1995, An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer’s disease, Lab. Invest. 72:272–282.
Prusiner, S.B., 1996, Priori biology and diseases-Laughing cannibals, mad cows, and scientific heresy, Med. Res. Rev. 16:487–505.
Prusiner, S.B., Telling, G., Cohen, F.E., and DeArmond, S.J., 1996, Prion diseases of humans and animals, Semin. Virol. 7:159–173.
Roses, A.D., 1996, The Alzheimer diseases, Curr. Opin. Neurobiol. 6:644–650.
Saraiva, M.J.M., 1995, Transthyretin mutations in health and disease, Hum. Mutat. 5:191–196.
Solomon, A., Weiss, D.T., and Pepys, M.B., 1992, Induction mice of human light-chain-associated amyloidosis, Am. J. Pathol. 140:629–637.
Tagouri, Y.M., Sanders, P.W., Picken, M.M., Siegal, G.P., Kerby, J.D., and Herrera, G.A., 1996, In vitro AL-Amy-loid formation by rat and human mesangial cells, Lab. Invest. 74:290–302.
Verchere, C.B., D’Alessio, D.A., Palmiter, R.D., Weir, G.C., Bonner-Weir, S., Baskin, D.G., and Kahn, S.E., 1996, Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide, Proc. Natl. Acad. Sci. USA 93:3492–3496.
Westermark, P., Engstrom, U., Johnson, K.H., Westermark, G.T., and Betsholtz, C., 1990, Islet Amyloid Polypeptide-Pinpointing Amino Acid Residues Linked to Amyloid Fibril Formation, Proc. Natl. Acad. Sci. USA 87:5036–5040.
Yamamura, K., Tashiro, F., Yi, S., Wakasugi, S., Araki, S., Maeda, S., and Shimada, K., 1993, Transgenic Mouse Model for Human Genetic Diseases, Mol. Reprod. Dev. 36:248–250.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kisilevsky, R. (1998). Animal Models of Amyloid Aggregation and Deposition. In: Fisher, A., Hanin, I., Yoshida, M. (eds) Progress in Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 49. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5337-3_31
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5337-3_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7435-0
Online ISBN: 978-1-4615-5337-3
eBook Packages: Springer Book Archive